Equillium, Inc. (NASDAQ:EQ) Stock Has Consensus Target Price of $7.57

Equillium, Inc. (NASDAQ:EQ) has been given an average recommendation of “Moderate Buy” by the eleven ratings firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $7.57.

A number of analysts have recently weighed in on EQ shares. Roth Capital reaffirmed a “buy” rating and issued a $12.00 price target on shares of Equillium in a research note on Friday, September 4th. Clear Str raised Equillium to a “strong-buy” rating in a research report on Tuesday, July 21st. Wall Street Zen cut shares of Equillium from a “hold” rating to a “sell” rating in a research note on Saturday, September 19th. Leerink Partners initiated coverage on Equillium in a research report on Monday, October 12th. They set an “outperform” rating and a $6.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Equillium in a research note on Monday, September 21st.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Janus Henderson Group PLC boosted its stake in Equillium by 10.8% in the first quarter. Janus Henderson Group PLC now owns 6,494,571 shares of the company’s stock valued at $12,957,000 after buying an additional 632,359 shares in the last quarter. Jupiter Topco LLC bought a new position in Equillium during the second quarter valued at $20,685,000. ADAR1 Capital Management LLC purchased a new stake in shares of Equillium during the second quarter worth $12,027,000. Eversept Partners LP purchased a new position in shares of Equillium during the 1st quarter valued at $2,998,000. Finally, Affinity Asset Advisors LLC purchased a new stake in Equillium in the first quarter worth approximately $2,453,000. 27.05% of the stock is owned by institutional investors and hedge funds.

Equillium Price Performance

Shares of NASDAQ EQ opened at $1.23 on Friday. Equillium has a 12 month low of $0.76 and a 12 month high of $3.54. The company has a market cap of $77.99 million, a PE ratio of -6.15 and a beta of 1.93. The company has a 50-day simple moving average of $1.86 and a 200-day simple moving average of $2.25.

Equillium (NASDAQ:EQ) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.01. On average, analysts anticipate that Equillium will post -0.21 EPS for the current year.

Equillium Company Profile

Equillium, Inc is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory diseases. The company’s approach centers on modulating immune pathways involved in disease progression, with the goal of addressing conditions that have limited treatment options.

Equillium’s lead product candidate is itolizumab, a monoclonal antibody that targets CD6, an immune-cell receptor involved in the regulation of T-cell activity. The company is evaluating itolizumab in immune-mediated conditions, including acute graft-versus-host disease and lupus nephritis.